[REVISION HISTORY]

Corcept Therapeutics stock volatility and insider trading

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-21 11:31 UTC → 2026-08-21 22:29 UTC · added ~~removed~~

Corcept Therapeutics experienced a significant stock surge of approximately 228%, reaching a price of $117.17 by August 18, 2026. This growth was linked to an investment by Donald Trump, FDA support for a New Drug Application regarding relacorilant, and positive clinical trial results presented at the American Society of Clinical Oncology annual meeting. Following the price increase, SEC filings indicated insider selling activity. On August 18, Corcept Therapeutics Director David Mahoney sold 103,606 shares at an average price of $118.25, a transaction totaling roughly $12.25 million. This sale reduced his total stake in the company by 8.37%. By August 20, Corcept Therapeutics reported quarterly earnings of $0.36 per share, which exceeded analyst estimates.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.